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112 Poster Session IIsource: 119 PB/31 BM) were retrospectively analyzed. Their diag-
noses were 90 acute leukemia, 30 CML, 6 MDS and 24 other dis-
eases. Multiplex PCR method was performed to amplify 16 STR
loci (D3S1358, HUMvWA, D16S539, D2S1338, Amelogenin,
D8S1179, D21S11, D18S51, D19S433, THO1, FGA, D7S820,
CSF1PO, D13S317, TPOX, D5S818) (ABI Prism 3130). The loci
examined were classified as complete matched (CM), partially
matched (PM), and fully mismatched (FMM) between donors and
recipients.
Results: The loci of D13S317, D18S51 and D2S1338 were the
most informative, while the loci of TPOX and CSF1PO were the
least. The incidence of acute GvHD was 46.7% (n 5 69), which
acute severe GvHD (grII-IV) was observed in only 31 patients.
Chronic GvHD was developed in 63.4% patients. The incidence
of grII-IV GvHD was higher in patient with CM in TPOX loci
(p 5 0.02). Chronic GvHD was more frequent in the patients
with PM in D5S818 loci than those with CM or MM (p 5 0.016).
While PMD21S11 increasedTRM,MMor PM inD5S818 loci de-
creased the TRM. In our cohort analysis, 2-year probability of dis-
ease-free survival(DFS) and overall survival(OS) were 58.1 6 5.5%
and 67.56 4.4%, respectively. TheCM inD21D11 locus (p5 0.07)
and PM in D5S818 locus (p 5 0.009) prolonged the probability of
DFS. In multivariate analysis, these loci had an impact onDFS (p5
0.055 ve p5 0.005). D19S433 and D5S818 loci had an effect on the
OS. We repeated similar analyses into two groups, mismatched
(MM) group, which FMM and PM was accepted as a whole group
or CM group, while the incidence of grII-IV GvHD was higher
in patients with CM of D18S51 and TPOX loci, the chronic
GvHD was more frequent in those with CM D5S820 loci. Similar
as the first analyses MM in D21S11 and CM in D5S818 affected
both TRM and DFS. Besides, MM in FGA locus decreased TRM
and prolonged DFS. The impact of D5S818 on the OS also contin-
ued, additionallyD19S433 hadminimal effect on theOS. In conclu-
sion, some disparities of STR loci might affect the transplantation
outcome; however, these results should be analyzed together with
other co-variates and on multicenter basis.302
AN EVALUATION OF DNA METHYLATION CHANGES IN A PHASE I CLIN-
ICAL TRIAL OF LOW-DOSE 5-AZACITIDINE (AZA) GIVEN AS MAINTE-
NANCE THERAPY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION (HSCT)
Silva, L.1, Garcia-Manero, G.2, Giralt, S.1, McCormick, G.1,
Soriano, A.2, Champlin, R.1, Kantarjian, H.2, de Lima, M.1. 1 The Uni-
versity of Texas MD Anderson Cancer Center, Houston, TX; 2 The Uni-
versity of Texas MD Anderson Cancer Center, Houston, TX.
DNA methylation of CpG Islands is a frequently found epige-
netic alteration in AML andMDS that leads to deranged gene activ-
ity. Inhibition of the enzyme DNA methyltransferase is associated
with hypomethylation, and possibly, restoration of normal function
to genes critical for differentiation and proliferation. AZA is a DNA
hypomethylating agent that may induce increased tumor immuno-
genicity, potentially magnifying the GVL effect. Lower doses are
likely to be better tolerated after HSCT and to be effective inducers
of hypomethylation. We hypothesized that AZA after HSCT will
lower relapse rates, and designed a phase I clinical trial that also
uses a molecular surrogate endpoint for dose finding. Here we de-
scribe methylation changes in patients so treated.
Pts with AML or high-risk MDS not in first remission (CR) are
eligible. Three doses of AZA were studied: 8, 16, and 24 mg/m2
daily  5 starting on day 1 42. DNA was extracted from mononu-
clear cells of 22 pts that received AZA. The methylation status of
long interspersed nuclear elements (LINE) was analyzed by pyrose-
quencing as a surrogate marker of global DNA methylation before
and after AZA administration. Gene specific methylation changes
were studied using a methylated CpG island amplification(MCA)/
CpG array.
Median age was 57 years. Diagnoses were MDS (n 5 4) and
AML(n5 18). Disease status atHSCT:CR, 18% (n5 4), and active
disease, 82%(n 5 18). LINE methylation results were as follows:
baseline: 44.51%; on cycle 1, 5th day of AZA: 24 mg/m2 5
43.58%; 16 mg/m2: 36.93%; 8 mg/m2: 42.86%. Two pts have re-lapsed while on AZA.There has been nomajor drug-related toxicity
and no increase in GVHD incidence. Analysis of gene-specific
methylation is ongoing.
AZA in doses up to 24 mg/m2 can be safely administered early af-
ter HSCT. Given the lack of toxicity and low levels of changes in
DNA methylation observed, we are currently investigating higher
doses.303
ROLE OF EXTENSIVE SPLENOMEGALY IN PATIENTS WITH MYELOFI-
BROSIS UNDERGOING A REDUCED INTENSITY ALLOGENEIC STEM
CELL TRANSPLANT
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Gaitonde, S.1, Dobogai, L.1, Akard, L.P.2, Hoffman, R.3,4,
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Allogeneic stem cell transplantation has been shown to restore
normal hematopoiesis in patients with intermediate or high risk pri-
mary myelofibrosis (PMF) or myelofibrosis preceeded by polycy-
themia vera or essential thrombocythemia. However, in patients
with PMF and extensive splenomegaly it is not clear whether trans-
plant is associated with an unacceptable risk or if splenectomy
should be performed prior to transplant. In this study, ten consec-
utive patients with myelofibrosis who were not splenectomized re-
ceived an allogeneic hematopoietic stem cell transplantation
(HSCT) from related or unrelated donors and were periodically
monitored by ultrasound or CT scan for 12 months after transplant
to assess the kinetics of the reduction of splenomegaly. These find-
ings were correlated with the time to resolution of marrow fibrosis,
time to engraftment and clinical outcome. Over a 12 month period
a progressive reduction in spleen size was observed in all the patients
and paralleled the reduction in marrow fibrosis. Of 10 patients, 5
with a splenic longitudinal diameter .30 cm showed a more pro-
longed time to engraftment ANC . 0.5  109/L (d 19 6 5 vs 13
6 2, p 5 0.05) and platelet . 20  109/L (d 75 6 104 vs 11 6 2,
p 5 0.06). However, of the 5 patients with more extensive spleno-
megaly only 2 experienced delayed engraftment of platelets (d 77
and 256, respectively). Full donor chimerism was observed in all pa-
tients within 60 days after transplantation regardless of the size of
the spleen. At a median follow-up of 51 months (range: 2–81) all
the patients are alive but 1 who died of a TTP like syndrome 2
months after transplant and had a small spleen at the time of trans-
plant. A clinical CR has been documented in 7 patients and 2 have
achieved clinical improvement according to to the criteria estab-
lished by the International Working Group for Myelofibrosis Re-
search and Treatment (IWG-MRT). These findings suggest that
allogeneic HSCT with RIC regimen can be safely performed in pa-
tients with extensive splenomegaly. Although in these patients the
time to achieve a full hematopoietic engraftment may be prolonged,
the significant risk of morbidity and mortality associated with sple-
nectomy may be avoided.304
EFFECT OF SUBSTITUTING FLUDARABINE AND THYMOGLOBULIN FOR
CYCLOPHOSPHAMIDE IN BUSULFAN-BASED CONDITIONING REGIMENS
ON T-CELL CHIMERISM AND OUTCOMES AFTER ALLOGENEIC HEMATO-
POIETIC CELL TRANSPLANTATION (HCT)
O’Donnell, P.V.1, Woolfrey, A.E.1, Storer, B.1, Sorror, M.L.1,
Furlong, T.1, Anasetti, C.2, Heimfeld, S.1, Flowers, M.1,
Appelbaum, F.R.1, Martin, P.J.1, Deeg, H.J.1. 1 Fred Hutchinson Cancer
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Substitution of cyclophosphamide by agents such as fludarabine
and thymoglobulin in busulfan-based conditioning regimens has
been used to reduce complications after allogeneic HCT. We per-
formed a retrospective analysis of outcomes among 348 patients
